Physician profile
Lamia Boric
NPI 1689881898
$1,214.48
in general payments reported to CMS, 2019-2025
30 companies · $51.13 in 2025
The $51.13 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $437 · 2023: $436 · 2024: $136 · 2025: $51.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.71 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $155.49 | 2022-2023 | Calquence |
| Celgene Corporation | $85.58 | 2021-2022 | |
| Seagen INC. | $68.17 | 2021-2022 | |
| Cti Biopharma Corp. | $52.69 | 2022-2023 | Vonjo |
| E.R. Squibb & Sons, L.L.C. | $48.37 | 2022-2023 | Opdivo |
| Genentech USA, INC. | $44.31 | 2023 | Gavreto, Alecensa, Tecentriq |
| Pfizer INC. | $43.96 | 2022 | |
| Genzyme Corporation | $43.66 | 2022-2023 | |
| Eisai INC. | $43.44 | 2021-2023 | |
| Amgen INC. | $41.72 | 2022 | |
| Gilead Sciences, INC. | $37.29 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.75 | 2022-2023 | Keytruda |
| Emd Serono, INC. | $31.23 | 2021-2023 | Tepmetko |
| Bayer Healthcare Pharmaceuticals INC. | $30.73 | 2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $27.92 | 2022 | |
| Lilly USA, LLC | $27.01 | 2023 | Verzenio |
| Takeda Pharmaceuticals U.S.A., INC. | $20.43 | 2022 | |
| Mirati Therapeutics, INC. | $20.07 | 2023 | Krazati |
| Incyte Corporation | $19.97 | 2022 | |
| Jazz Pharmaceuticals INC. | $18.07 | 2023 | Zepzelca |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.32 | 2022 | |
| Kyowa Kirin, INC. | $16.11 | 2023 | Poteligeo |
| Pharmacyclics LLC, An Abbvie Company | $15.69 | 2023 | Imbruvica, Epkinly |
| Spectrum Pharmaceuticals INC. | $14.90 | 2023 | Rolvedon |
| Ipsen Biopharmaceuticals, INC | $13.82 | 2022 | |
| Morphosys, US INC. | $13.47 | 2021 | |
| Pharmacosmos Therapeutics INC. | $12.84 | 2023 | Monoferric |
| Janssen Pharmaceuticals, INC | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lamia Boric listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.